Anavex Life Sciences better have deep pockets and patience if they want to tackle neurodegenerative diseases like Alzheimer's and Parkinson's with their lead compound ANAVEXÂ®2-73. Not only do they have to compete with big players like Biogen, Pfizer, and Novartis, but they also have to navigate the complex legal and technical world of biomedical companies. And let's not forget the lengthy and expensive process of obtaining regulatory approval from governmental agencies, both in the US and abroad. But hey, at least they have good relations with their sixteen full-time employees and some highly regarded scientific advisors. And if you want to read more about their financial information and available reports, check out their website (but don't expect it to be an active link).